AUTHORS
Claire Horgan, MD, Katharina Kleinschmidt, MD2, Mouad Abouqateb3, Adriana Balduzzi, MD4, Giovanna Lucchini5, Jacques-Emmanuel Galimard6, Nathanael Lucas7, Krzysztof Czyzewski8, Peter Svec Sr, MD, PhD9, Jan Styczynski10, Gergely Kriván11, Joern-Sven Kuehl12, Marta Gonzalez Vicent13, Kanchan Rao14, Francis Chan15, Francesco Paolo Tambaro16, R.F. Wynn17, Subramaniam Ramanathan18, Alessandra Biffi, MD, PhD19, Ivan Lopez-Torija20, Renata Formankova21, Wolfgang Holter22, Christina Peters Sr, MD, PhD23, Tamara Diesch-Furlanetto24, Andrea Urtasun25, Matthias Woelfl26, Jowita Fraczkiewicz27, Maria Ester Bernardo28, Michael H. Albert29, Agnieska Sobkowiak-Sobierajska30, Elif Ince31, Roland Meisel32, Arnaud Dalissier33, Selim Corbacioglu, MD34, Emanuele Angelucci35, Benedicte Neven Sr36, Krzysztof Kalwak, PhD, DSc37
AFFILIATIONS
1 Manchester University NHS Foundation Trust, Manchester, United Kingdom
2 University of Regensburg, Regensburg, Germany
3 EBMT Paris Study Unit, Paris, France
4 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
5 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
6 EBMT Paris Study Unit, Paris, France
7 Starship Hospital, Auckland, New Zealand
8 Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
9 National Institute of Children’s Diseases and Comenius University, Bratislava, Slovakia
10 Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
11 Central Hospital for Southern Pest National Institute of Hematology and Infectology, Budapest, Hungary
12 University of Leipzig Pediatric Oncology, Medical Clinic and Policinic 1, Leipzig, Germany
13 Nino Jesus Children's Hospital, Madrid, Spain
14 Great Ormond Street Children's Hospital, London, United Kingdom
15 Great Ormond Street Children's Hospital, London, United Kingdom
16 AORN Santobono Pausilipon, Napoli, Italy
17 Manchester University NHS Foundation Trust, Manchester, United Kingdom
18 Great North Children`s Hospital, Newcastle, United Kingdom
19 Azienda Ospedale Università, Padova, Italy
20 Hospital Santa Creu i Sant Pau Department of Pediatrics, Barcelona, Spain
21 University Hospital Motol,, Prague, Czech Republic
22 St. Anna Hilten‘s Research Institute, Vienna, Austria
23 St. Anna Hilten‘s Research Institute, Vienna, Austria
24 University Children´s Hospital of Basel, Basel, Switzerland
25 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
26 University Children`s Hospital of Würzburg, Würzburg, Germany
27 Wroclaw Medical University, Wroclaw, Poland
28 IRCCS San Raffaele Hospital, Milan, Italy
29 Dr. von Hauner Children’s Hospital, Munich, Germany
30 University of Medical Sciences, Poznan, Poland
31 Ankara University Medical Faculty, Ankara, Turkey
32 Heinrich Heine University, Düsseldorf, Germany
33 EBMT Paris Study Unit, Paris, France
34 University of Regensburg, Regensburg, Germany
35 AOM-IRCCS Ospedale Policlinico San Martino, Genova, Italy
36 INSERM UMR 1163-Institut Imagine, Paris, France
37 Wroclaw Medical University, Wroclaw, Poland
ABSTRACT
Background: Cytomegalovirus (CMV) remains a major cause of morbidity after hematopoietic stem cell transplantation (HSCT). Although letermovir is licensed for CMV prophylaxis in adults and children, real-world evidence in children remains limited. We evaluated the effectiveness and safety of letermovir in the largest international cohort of pediatric allogeneic HSCT recipients aged <12 years.
Methods: We conducted a retrospective multicenter cohort study through the Paediatric Diseases (PDWP), Inborn Errors (IEWP) and Haemoglobinopathies (HWP) Working Parties of the European Society for Blood and Marrow Transplantation (EBMT). Children aged <12 years who received letermovir as primary or secondary CMV prophylaxis after allogeneic HSCT between 2019 and 2024 were included. The primary endpoint was cumulative incidence (CI) of CMV reactivation. Secondary endpoints included CMV disease, CMV-related mortality, overall survival (OS), progression-free survival (PFS), relapse incidence (RI), non-relapse mortality (NRM), safety, and management of CMV reactivation. Time-to-event outcomes were calculated using competing-risk and Kaplan-Meier methods. An exploratory cause-specific Cox model evaluated the association between donor-recipient serostatus and CMV reactivation, adjusting for prophylaxis indication, malignant disease, and PTCy use.
Results: A total of 146 children were included, with 115 (78.8%) receiving primary prophylaxis and 31 (21.2%) secondary prophylaxis. Letermovir was initiated early in patients receiving primary prophylaxis, with a median start of 1 day after HSCT (IQR 0–5 days), whereas patients with secondary prophylaxis initiated treatment at a median of 64 days after HSCT [IQR 3–107 days]; p<0.001. Median age at letermovir initiation was 7.2 years (range, 0.1-11.9), with comparable distributions between groups, and median follow-up was 1.0 year (95% CI, 0.9-1.1).
The 1-year CI of CMV reactivation was 24.3% (95% CI, 17.2-31.5): 22.1% (95% CI, 14.3-30.0) with primary prophylaxis and 32.6% (95% CI, 16.0-49.3) with secondary prophylaxis. Most CMV reactivations occurred within 6 months of letermovir initiation, with a 6-month CI of 23.5% (95% CI, 16.5–30.6) overall. At 1 year, the incidence of CMV reactivation was highest among donor-negative/recipient-positive (D-/R+) patients at 33.9% (95% CI, 21.4–46.4), compared with 19.8% (95% CI, 10.2–29.5) among D+/R+ patients and 7.1% (95% CI, 0.0–20.6) among D+/R− patients. In the exploratory adjusted Cox model, donor–recipient CMV serostatus was independently associated with CMV reactivation (P=0.019). CMV sero-positive recipients experienced the highest CI of CMV reactivation when grafted from CMV-seronegative donor compared with those grafted from sero-positive ones (33.9% vs 17.3% at 1 year).
No cases of CMV disease or CMV-related mortality were observed. All breakthrough reactivations responded to standard antiviral therapy, with viral clearance achieved in all but one patient at last follow up.
One-year OS and PFS were 87.4% and 83.3%, respectively, while RI and NRM were 9.5% and 7.2%. Letermovir was very well tolerated, with only two mild gastrointestinal adverse events and no clinically significant drug-related toxicities or treatment discontinuations.
Conclusions: In this large international multicenter cohort of children aged <12 years undergoing allogeneic HSCT, letermovir prophylaxis was associated with low rates of CMV reactivation, excellent tolerability, no CMV disease or CMV-related mortality, and favorable survival outcomes. As expected, CMV reactivation was highest among D−/R+ patients (33.9%), but this rate was significantly lower than the approximately 51% reported in other studies. These findings strongly support the use of letermovir in pediatric HSCT and provide a rationale for prospective studies to optimize prophylaxis strategies, particularly in high-risk donor-recipient serostatus groups.
DISCLOSURES
Krzysztof Kalwak, PhD, DSc: No relevant conflicts of interest to declare.